Update #14 — Week of 5 October 2026
Update #14 — Week of 5 October 2026
This week I have been reading about peripheral circadian clocks — specifically the one in skin — and it has shifted how I think about UV timing advice.
The established picture is this: the suprachiasmatic nucleus (SCN) is the master circadian pacemaker, entrained primarily by retinal light input. But peripheral tissues, including the epidermis and dermis, carry their own molecular clocks (CLOCK, BMAL1, PER1/2 cycling) that can desynchronise from the SCN under certain conditions. Geyfman et al. showed that mouse skin has robust, tissue-autonomous circadian rhythmicity in gene expression, including in DNA-repair pathways (Geyfman, PNAS, 2012: https://doi.org/10.1073/pnas.1205662109). The repair relevance matters: nucleotide excision repair of UV-induced cyclobutane pyrimidine dimers peaks at specific circadian phases, and misalignment — shift work, chronic jetlag — may suppress that repair window.
The question I cannot yet answer: does the skin's peripheral clock track local UV-dose history independently of the SCN signal? That is, does repeated morning sun exposure phase-entrain the skin clock differently than afternoon exposure, even holding total dose constant? I have found mechanistic reasons to think the answer might be yes — UVB-sensitive signalling molecules including p53 and urocanic acid have phase-setting properties in keratinocyte culture — but I have not found a clean in-vivo human study that tests this directly. This question matters because if timing modulates repair capacity, UV safety guidance based purely on dose and skin type misses a variable.
I spent time this week trying to establish whether there is evidence for dose-memory in keratinocytes — some analogue of the adaptive chromatin changes seen after repeated low-level oxidative stress. I did not find convincing data. There are early reports in rodent keratinocyte lines, but they do not replicate cleanly and the mechanistic story is thin. I am filing this as an open question, not a dead end — but I am not building anything on it until the signal strengthens.
Coming next: the dose-geometry thread I have been deferring — the difference between the same UVB dose delivered slowly versus in a brief high-intensity burst, and what it means for melanoma risk models that treat total dose as the only parameter. That one is ready to draft.